Benefits and risks to mother and infant of drug treatment for postnatal depression

The postnatal period presents a special problem to healthcare providers treating psychiatric disorders in women. Many new mothers who need antidepressant treatment may wish to breastfeed their infants, but are hesitant to do so for fear of passing on possible harmful effects of the medication throug...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug safety 2002, Vol.25 (13), p.903-911
Hauptverfasser: MISRI, Shaila, KOSTARAS, Xanthoula
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 911
container_issue 13
container_start_page 903
container_title Drug safety
container_volume 25
creator MISRI, Shaila
KOSTARAS, Xanthoula
description The postnatal period presents a special problem to healthcare providers treating psychiatric disorders in women. Many new mothers who need antidepressant treatment may wish to breastfeed their infants, but are hesitant to do so for fear of passing on possible harmful effects of the medication through their milk. The focus of this article will be on highlighting and interpreting the existing literature on the benefits and risks to mother and infant of drug treatment for postnatal depression, as well as outlining treatment guidelines for the use of antidepressants in breastfeeding mothers. The article will specifically focus on the use of fluoxetine, sertraline, paroxetine, fluvoxamine and citalopram, which are more commonly used and belong to the selective serotonin reuptake inhibitor group of antidepressants. The tricyclic and other newer antidepressant medications will also be discussed. As there are no published controlled studies on the use of antidepressants by breastfeeding women, publications of individual case reports, case series, and pharmacokinetic investigations serve as the basis for the development of treatment guidelines. Results from this growing body of literature are promising in that, with the exception of a few cases, no serious adverse events have been reported in infants exposed to antidepressant medications through breast milk. In addition nonpharmacological treatments consisting of different types of psychotherapies will be discussed. It is critical that healthcare providers evaluate each mother-infant dyad on an individual basis when faced with the decision to prescribe antidepressant medications during the postnatal period.
doi_str_mv 10.2165/00002018-200225130-00002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72180165</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18640033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-18554a314a738b820221119a2ea3816f24321bda8e89f2c7d6dbcc3cf474973a3</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhj2AaCn8BeQFtoDPdhJnhIovqRISgjm6OjYEkjjYzsC_x9BCR2456dFzH3oJocDOORT5BUvFGaiMp85zECz7QXtkzgBklldQzMhhCG-JKl6oAzIDLhRw4HPyeGUGY9sYKA4N9W14DzQ62rv4avwPaweLQ6TO0sZPLzR6g7E3iVjn6ehCHDBiRxszehNC64Yjsm-xC-Z42xfk-eb6aXmXrR5u75eXq0yLkscMVJ5LFCCxFGqteHoeACrkBtNzheVScFg3qIyqLNdlUzRrrYW2spRVKVAsyNlm7-jdx2RCrPs2aNN1OBg3hbrkoFhK6F8RVCEZEyKJaiNq70Lwxtajb3v0nzWw-jvs-jfs-i_sDUqjJ9sb07o3zW5wm3QSTrcCBo2d9TjoNuw8KSvBcyG-ACssiAo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18640033</pqid></control><display><type>article</type><title>Benefits and risks to mother and infant of drug treatment for postnatal depression</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>MISRI, Shaila ; KOSTARAS, Xanthoula</creator><creatorcontrib>MISRI, Shaila ; KOSTARAS, Xanthoula</creatorcontrib><description>The postnatal period presents a special problem to healthcare providers treating psychiatric disorders in women. Many new mothers who need antidepressant treatment may wish to breastfeed their infants, but are hesitant to do so for fear of passing on possible harmful effects of the medication through their milk. The focus of this article will be on highlighting and interpreting the existing literature on the benefits and risks to mother and infant of drug treatment for postnatal depression, as well as outlining treatment guidelines for the use of antidepressants in breastfeeding mothers. The article will specifically focus on the use of fluoxetine, sertraline, paroxetine, fluvoxamine and citalopram, which are more commonly used and belong to the selective serotonin reuptake inhibitor group of antidepressants. The tricyclic and other newer antidepressant medications will also be discussed. As there are no published controlled studies on the use of antidepressants by breastfeeding women, publications of individual case reports, case series, and pharmacokinetic investigations serve as the basis for the development of treatment guidelines. Results from this growing body of literature are promising in that, with the exception of a few cases, no serious adverse events have been reported in infants exposed to antidepressant medications through breast milk. In addition nonpharmacological treatments consisting of different types of psychotherapies will be discussed. It is critical that healthcare providers evaluate each mother-infant dyad on an individual basis when faced with the decision to prescribe antidepressant medications during the postnatal period.</description><identifier>ISSN: 0114-5916</identifier><identifier>DOI: 10.2165/00002018-200225130-00002</identifier><identifier>PMID: 12381212</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Antidepressive Agents - therapeutic use ; Antidepressive Agents, Tricyclic - therapeutic use ; Biological and medical sciences ; Breast Feeding - psychology ; Cognitive Therapy - methods ; Depression, Postpartum - drug therapy ; Depression, Postpartum - therapy ; Drug toxicity and drugs side effects treatment ; Female ; Humans ; Infant, Newborn ; Medical sciences ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Pharmacology. Drug treatments ; Psychotherapy, Group - methods ; Risk Assessment - methods ; Serotonin Uptake Inhibitors - therapeutic use</subject><ispartof>Drug safety, 2002, Vol.25 (13), p.903-911</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-18554a314a738b820221119a2ea3816f24321bda8e89f2c7d6dbcc3cf474973a3</citedby><cites>FETCH-LOGICAL-c372t-18554a314a738b820221119a2ea3816f24321bda8e89f2c7d6dbcc3cf474973a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4021,27921,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14493253$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12381212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MISRI, Shaila</creatorcontrib><creatorcontrib>KOSTARAS, Xanthoula</creatorcontrib><title>Benefits and risks to mother and infant of drug treatment for postnatal depression</title><title>Drug safety</title><addtitle>Drug Saf</addtitle><description>The postnatal period presents a special problem to healthcare providers treating psychiatric disorders in women. Many new mothers who need antidepressant treatment may wish to breastfeed their infants, but are hesitant to do so for fear of passing on possible harmful effects of the medication through their milk. The focus of this article will be on highlighting and interpreting the existing literature on the benefits and risks to mother and infant of drug treatment for postnatal depression, as well as outlining treatment guidelines for the use of antidepressants in breastfeeding mothers. The article will specifically focus on the use of fluoxetine, sertraline, paroxetine, fluvoxamine and citalopram, which are more commonly used and belong to the selective serotonin reuptake inhibitor group of antidepressants. The tricyclic and other newer antidepressant medications will also be discussed. As there are no published controlled studies on the use of antidepressants by breastfeeding women, publications of individual case reports, case series, and pharmacokinetic investigations serve as the basis for the development of treatment guidelines. Results from this growing body of literature are promising in that, with the exception of a few cases, no serious adverse events have been reported in infants exposed to antidepressant medications through breast milk. In addition nonpharmacological treatments consisting of different types of psychotherapies will be discussed. It is critical that healthcare providers evaluate each mother-infant dyad on an individual basis when faced with the decision to prescribe antidepressant medications during the postnatal period.</description><subject>Antidepressive Agents - therapeutic use</subject><subject>Antidepressive Agents, Tricyclic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast Feeding - psychology</subject><subject>Cognitive Therapy - methods</subject><subject>Depression, Postpartum - drug therapy</subject><subject>Depression, Postpartum - therapy</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Medical sciences</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychotherapy, Group - methods</subject><subject>Risk Assessment - methods</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><issn>0114-5916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkD1PwzAQhj2AaCn8BeQFtoDPdhJnhIovqRISgjm6OjYEkjjYzsC_x9BCR2456dFzH3oJocDOORT5BUvFGaiMp85zECz7QXtkzgBklldQzMhhCG-JKl6oAzIDLhRw4HPyeGUGY9sYKA4N9W14DzQ62rv4avwPaweLQ6TO0sZPLzR6g7E3iVjn6ehCHDBiRxszehNC64Yjsm-xC-Z42xfk-eb6aXmXrR5u75eXq0yLkscMVJ5LFCCxFGqteHoeACrkBtNzheVScFg3qIyqLNdlUzRrrYW2spRVKVAsyNlm7-jdx2RCrPs2aNN1OBg3hbrkoFhK6F8RVCEZEyKJaiNq70Lwxtajb3v0nzWw-jvs-jfs-i_sDUqjJ9sb07o3zW5wm3QSTrcCBo2d9TjoNuw8KSvBcyG-ACssiAo</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>MISRI, Shaila</creator><creator>KOSTARAS, Xanthoula</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>2002</creationdate><title>Benefits and risks to mother and infant of drug treatment for postnatal depression</title><author>MISRI, Shaila ; KOSTARAS, Xanthoula</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-18554a314a738b820221119a2ea3816f24321bda8e89f2c7d6dbcc3cf474973a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antidepressive Agents - therapeutic use</topic><topic>Antidepressive Agents, Tricyclic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast Feeding - psychology</topic><topic>Cognitive Therapy - methods</topic><topic>Depression, Postpartum - drug therapy</topic><topic>Depression, Postpartum - therapy</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Medical sciences</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychotherapy, Group - methods</topic><topic>Risk Assessment - methods</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MISRI, Shaila</creatorcontrib><creatorcontrib>KOSTARAS, Xanthoula</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MISRI, Shaila</au><au>KOSTARAS, Xanthoula</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benefits and risks to mother and infant of drug treatment for postnatal depression</atitle><jtitle>Drug safety</jtitle><addtitle>Drug Saf</addtitle><date>2002</date><risdate>2002</risdate><volume>25</volume><issue>13</issue><spage>903</spage><epage>911</epage><pages>903-911</pages><issn>0114-5916</issn><abstract>The postnatal period presents a special problem to healthcare providers treating psychiatric disorders in women. Many new mothers who need antidepressant treatment may wish to breastfeed their infants, but are hesitant to do so for fear of passing on possible harmful effects of the medication through their milk. The focus of this article will be on highlighting and interpreting the existing literature on the benefits and risks to mother and infant of drug treatment for postnatal depression, as well as outlining treatment guidelines for the use of antidepressants in breastfeeding mothers. The article will specifically focus on the use of fluoxetine, sertraline, paroxetine, fluvoxamine and citalopram, which are more commonly used and belong to the selective serotonin reuptake inhibitor group of antidepressants. The tricyclic and other newer antidepressant medications will also be discussed. As there are no published controlled studies on the use of antidepressants by breastfeeding women, publications of individual case reports, case series, and pharmacokinetic investigations serve as the basis for the development of treatment guidelines. Results from this growing body of literature are promising in that, with the exception of a few cases, no serious adverse events have been reported in infants exposed to antidepressant medications through breast milk. In addition nonpharmacological treatments consisting of different types of psychotherapies will be discussed. It is critical that healthcare providers evaluate each mother-infant dyad on an individual basis when faced with the decision to prescribe antidepressant medications during the postnatal period.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>12381212</pmid><doi>10.2165/00002018-200225130-00002</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0114-5916
ispartof Drug safety, 2002, Vol.25 (13), p.903-911
issn 0114-5916
language eng
recordid cdi_proquest_miscellaneous_72180165
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Antidepressive Agents - therapeutic use
Antidepressive Agents, Tricyclic - therapeutic use
Biological and medical sciences
Breast Feeding - psychology
Cognitive Therapy - methods
Depression, Postpartum - drug therapy
Depression, Postpartum - therapy
Drug toxicity and drugs side effects treatment
Female
Humans
Infant, Newborn
Medical sciences
Miscellaneous (drug allergy, mutagens, teratogens...)
Pharmacology. Drug treatments
Psychotherapy, Group - methods
Risk Assessment - methods
Serotonin Uptake Inhibitors - therapeutic use
title Benefits and risks to mother and infant of drug treatment for postnatal depression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T09%3A14%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benefits%20and%20risks%20to%20mother%20and%20infant%20of%20drug%20treatment%20for%20postnatal%20depression&rft.jtitle=Drug%20safety&rft.au=MISRI,%20Shaila&rft.date=2002&rft.volume=25&rft.issue=13&rft.spage=903&rft.epage=911&rft.pages=903-911&rft.issn=0114-5916&rft_id=info:doi/10.2165/00002018-200225130-00002&rft_dat=%3Cproquest_cross%3E18640033%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18640033&rft_id=info:pmid/12381212&rfr_iscdi=true